Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Ann Oncol
; 32(3): 323-336, 2021 03.
Article
in En
| MEDLINE
| ID: mdl-33307202
ABSTRACT
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breast cancer, there is a growing interest in combinatorial modalities, and particularly for their rapid development in the early disease setting. The plethora of ongoing immunotherapy trials in early breast cancer comes at a time when solid data in advanced disease are still imperfect. This review offers a perspective on the efforts to establish the efficacy and safety of immunotherapeutic agents in early breast cancer.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Triple Negative Breast Neoplasms
/
Immunotherapy
Limits:
Humans
Language:
En
Year:
2021
Type:
Article